<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02756624</url>
  </required_header>
  <id_info>
    <org_study_id>15-100-0010</org_study_id>
    <nct_id>NCT02756624</nct_id>
  </id_info>
  <brief_title>A Multi-Center, Vehicle-Controlled, Parallel-Group Study Evaluating the Safety of AC-170 Ophthalmic Solution</brief_title>
  <official_title>A Multi-Center, Double-Masked, Randomized, Vehicle-Controlled, Parallel-Group Study Evaluating the Safety of AC-170 Ophthalmic Solution</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Nicox Ophthalmics, Inc</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>ORA, Inc.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Nicox Ophthalmics, Inc</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is study is evaluating the safety and tolerability of AC-170 Ophthalmic Solution
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Central Cornea Endothelial Cell Counts will be done on a subset of approximately 150 subjects
      to complete 100 subjects as part of the safety measures.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>April 2016</start_date>
  <completion_date type="Actual">August 2016</completion_date>
  <primary_completion_date type="Actual">August 2016</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Tolerability of AC 170 0.24% at Visit 1 (Day 1)</measure>
    <time_frame>Upon instillation, 30 Seconds Post-Instillation, 1 minute Post-Instillation</time_frame>
    <description>Tolerability was assessed upon instillation of study medication, at 1 minute and 2 minutes post study medication instillation. Drop comfort was assessed using a 0-to 10 scale where 0=very comfortable and 10=very uncomfortable.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Tolerability of AC 170 0.24% at Visit 2 (Day 8)</measure>
    <time_frame>Upon instillation, 30 Seconds Post-Instillation, 1 minute Post-Instillation</time_frame>
    <description>Tolerability was assessed upon instillation of study medication, at 1 minute and 2 minutes post study medication instillation. Drop comfort was assessed using a 0-to 10 scale where 0=very comfortable and 10=very uncomfortable.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Tolerability of AC 170 0.24% at Visit 3 (Day 22)</measure>
    <time_frame>Upon instillation, 30 Seconds Post-Instillation, 1 minute Post-Instillation</time_frame>
    <description>Tolerability was assessed upon instillation of study medication, at 1 minute and 2 minutes post study medication instillation. Drop comfort was assessed using a 0-to 10 scale where 0=very comfortable and 10=very uncomfortable.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Treatment Related Adverse Events</measure>
    <time_frame>up to 12 weeks</time_frame>
    <description>Adverse events will be measured through study completion</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">516</enrollment>
  <condition>Healthy Subjects</condition>
  <arm_group>
    <arm_group_label>AC-170 0.24%</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>1 drop in each eye 3 times daily for up to 6 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>AC-170 Vehicle</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>1 drop in each eye 3 times daily for up to 6 weeks</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>AC-170 0.24%</intervention_name>
    <arm_group_label>AC-170 0.24%</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>AC-170 Vehicle</intervention_name>
    <arm_group_label>AC-170 Vehicle</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  at least 2 years of age

          -  be able to self-administer eye drops or have a parent/legal guardian available for
             this purpose

          -  if less than 18 years old have a history or family history of atopic disease
             (including allergic conjunctivitis)

          -  have ocular health within normal limits

        Exclusion Criteria:

          -  known contraindications or sensitivities to the study medication or its components

          -  any ocular condition that, in the opinion of the investigator, could affect the
             subjects safety trial parameters

          -  use of disallowed medication during the period indicated prior to the enrollment or
             during the study

          -  be pregnant, nursing, or planning a pregnancy
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>2 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Eugene Protzko, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Sedeinberg Protzko Eye Associates</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Ranjan Malhotra, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Ophthalmology Associates</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Stacey Ackerman, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Philadelphia Eye Associates</affiliation>
  </overall_official>
  <overall_official>
    <last_name>M. Ali Haider, DO</last_name>
    <role>Principal Investigator</role>
    <affiliation>Haider Eye Care</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Robert Rice, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>R&amp;R Eye Research</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Gail Torkildsen, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Andover Eye Associates</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Ora Clinical Site Network</name>
      <address>
        <city>Andover</city>
        <state>Massachusetts</state>
        <zip>01810</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>September 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 20, 2016</study_first_submitted>
  <study_first_submitted_qc>April 26, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 29, 2016</study_first_posted>
  <results_first_submitted>June 27, 2017</results_first_submitted>
  <results_first_submitted_qc>June 27, 2017</results_first_submitted_qc>
  <results_first_posted type="Actual">July 26, 2017</results_first_posted>
  <last_update_submitted>September 5, 2017</last_update_submitted>
  <last_update_submitted_qc>September 5, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">September 11, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ophthalmic Solutions</mesh_term>
    <mesh_term>Cetirizine</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Subjects were recruited from six sites in the US.</recruitment_details>
      <pre_assignment_details>There were 516 subjects enrolled, 23 subjects discontinued, and 493 subjects completed the study. Participant flow and baseline characteristics are presented for the 516 subjects that met all inclusion criteria and none of the exclusion criteria and were randomized to receive AC-170 0.24% or AC-170 Vehicle.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>AC-170 0.24%</title>
          <description>1 drop in each eye 3 times daily for up to 6 weeks
AC-170 0.24%</description>
        </group>
        <group group_id="P2">
          <title>AC-170 Vehicle</title>
          <description>1 drop in each eye 3 times daily for up to 6 weeks
AC-170 Vehicle</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="343"/>
                <participants group_id="P2" count="173"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="327"/>
                <participants group_id="P2" count="166"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="16"/>
                <participants group_id="P2" count="7"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>AC-170 0.24%</title>
          <description>1 drop in each eye 3 times daily for up to 6 weeks
AC-170 0.24%</description>
        </group>
        <group group_id="B2">
          <title>AC-170 Vehicle</title>
          <description>1 drop in each eye 3 times daily for up to 6 weeks
AC-170 Vehicle</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="343"/>
            <count group_id="B2" value="173"/>
            <count group_id="B3" value="516"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="32.5" spread="16.81"/>
                    <measurement group_id="B2" value="31.8" spread="18.3"/>
                    <measurement group_id="B3" value="32.2" spread="17.31"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age, Customized</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>2-6 years old</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="18"/>
                    <measurement group_id="B2" value="12"/>
                    <measurement group_id="B3" value="31"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>2 years old</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                    <measurement group_id="B2" value="8"/>
                    <measurement group_id="B3" value="14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>3 years old</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>7-12 years old</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="29"/>
                    <measurement group_id="B2" value="15"/>
                    <measurement group_id="B3" value="44"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>4-12 years old</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="36"/>
                    <measurement group_id="B2" value="17"/>
                    <measurement group_id="B3" value="53"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>13-17 years old</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="37"/>
                    <measurement group_id="B2" value="17"/>
                    <measurement group_id="B3" value="54"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;/= 18 years old</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="259"/>
                    <measurement group_id="B2" value="129"/>
                    <measurement group_id="B3" value="388"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="197"/>
                    <measurement group_id="B2" value="102"/>
                    <measurement group_id="B3" value="299"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="146"/>
                    <measurement group_id="B2" value="71"/>
                    <measurement group_id="B3" value="217"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="58"/>
                    <measurement group_id="B2" value="40"/>
                    <measurement group_id="B3" value="98"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="285"/>
                    <measurement group_id="B2" value="133"/>
                    <measurement group_id="B3" value="418"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="11"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="3"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="53"/>
                    <measurement group_id="B2" value="32"/>
                    <measurement group_id="B3" value="85"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="270"/>
                    <measurement group_id="B2" value="126"/>
                    <measurement group_id="B3" value="396"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="4"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                    <measurement group_id="B2" value="9"/>
                    <measurement group_id="B3" value="16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="343"/>
                    <measurement group_id="B2" value="173"/>
                    <measurement group_id="B3" value="516"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Tolerability of AC 170 0.24% at Visit 1 (Day 1)</title>
        <description>Tolerability was assessed upon instillation of study medication, at 1 minute and 2 minutes post study medication instillation. Drop comfort was assessed using a 0-to 10 scale where 0=very comfortable and 10=very uncomfortable.</description>
        <time_frame>Upon instillation, 30 Seconds Post-Instillation, 1 minute Post-Instillation</time_frame>
        <population>Intent to Treat (ITT)</population>
        <group_list>
          <group group_id="O1">
            <title>AC-170 0.24%</title>
            <description>1 drop in each eye 3 times daily for up to 6 weeks
AC-170 0.24%</description>
          </group>
          <group group_id="O2">
            <title>AC-170 Vehicle</title>
            <description>1 drop in each eye 3 times daily for up to 6 weeks
AC-170 Vehicle</description>
          </group>
        </group_list>
        <measure>
          <title>Tolerability of AC 170 0.24% at Visit 1 (Day 1)</title>
          <description>Tolerability was assessed upon instillation of study medication, at 1 minute and 2 minutes post study medication instillation. Drop comfort was assessed using a 0-to 10 scale where 0=very comfortable and 10=very uncomfortable.</description>
          <population>Intent to Treat (ITT)</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="309"/>
                <count group_id="O2" value="152"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Upon instillation</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.87" spread="1.435"/>
                    <measurement group_id="O2" value="0.50" spread="1.106"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>30 seconds post-instillation</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.64" spread="1.181"/>
                    <measurement group_id="O2" value="0.42" spread="0.982"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>1 minute post-instillation</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.42" spread="1.001"/>
                    <measurement group_id="O2" value="0.31" spread="0.822"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Tolerability of AC 170 0.24% at Visit 2 (Day 8)</title>
        <description>Tolerability was assessed upon instillation of study medication, at 1 minute and 2 minutes post study medication instillation. Drop comfort was assessed using a 0-to 10 scale where 0=very comfortable and 10=very uncomfortable.</description>
        <time_frame>Upon instillation, 30 Seconds Post-Instillation, 1 minute Post-Instillation</time_frame>
        <population>Intent to Treat (ITT)</population>
        <group_list>
          <group group_id="O1">
            <title>AC-170 0.24%</title>
            <description>1 drop in each eye 3 times daily for up to 6 weeks
AC-170 0.24%</description>
          </group>
          <group group_id="O2">
            <title>AC-170 Vehicle</title>
            <description>1 drop in each eye 3 times daily for up to 6 weeks
AC-170 Vehicle</description>
          </group>
        </group_list>
        <measure>
          <title>Tolerability of AC 170 0.24% at Visit 2 (Day 8)</title>
          <description>Tolerability was assessed upon instillation of study medication, at 1 minute and 2 minutes post study medication instillation. Drop comfort was assessed using a 0-to 10 scale where 0=very comfortable and 10=very uncomfortable.</description>
          <population>Intent to Treat (ITT)</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="299"/>
                <count group_id="O2" value="149"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Upon instillation</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.65" spread="1.279"/>
                    <measurement group_id="O2" value="0.19" spread="0.665"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>30 seconds post-instillation</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.38" spread="0.872"/>
                    <measurement group_id="O2" value="0.24" spread="0.766"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>1 minute post-instillation</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.26" spread="0.801"/>
                    <measurement group_id="O2" value="0.21" spread="0.650"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Tolerability of AC 170 0.24% at Visit 3 (Day 22)</title>
        <description>Tolerability was assessed upon instillation of study medication, at 1 minute and 2 minutes post study medication instillation. Drop comfort was assessed using a 0-to 10 scale where 0=very comfortable and 10=very uncomfortable.</description>
        <time_frame>Upon instillation, 30 Seconds Post-Instillation, 1 minute Post-Instillation</time_frame>
        <population>Intent to Treat (ITT)</population>
        <group_list>
          <group group_id="O1">
            <title>AC-170 0.24%</title>
            <description>1 drop in each eye 3 times daily for up to 6 weeks
AC-170 0.24%</description>
          </group>
          <group group_id="O2">
            <title>AC-170 Vehicle</title>
            <description>1 drop in each eye 3 times daily for up to 6 weeks
AC-170 Vehicle</description>
          </group>
        </group_list>
        <measure>
          <title>Tolerability of AC 170 0.24% at Visit 3 (Day 22)</title>
          <description>Tolerability was assessed upon instillation of study medication, at 1 minute and 2 minutes post study medication instillation. Drop comfort was assessed using a 0-to 10 scale where 0=very comfortable and 10=very uncomfortable.</description>
          <population>Intent to Treat (ITT)</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="295"/>
                <count group_id="O2" value="148"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Upon instillation</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.66" spread="1.321"/>
                    <measurement group_id="O2" value="0.43" spread="1.036"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>30 seconds post-instillation</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.37" spread="0.942"/>
                    <measurement group_id="O2" value="0.25" spread="0.725"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>1 minute post-instillation</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.24" spread="0.715"/>
                    <measurement group_id="O2" value="0.14" spread="0.446"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Number of Treatment Related Adverse Events</title>
        <description>Adverse events will be measured through study completion</description>
        <time_frame>up to 12 weeks</time_frame>
        <population>Intent to Treat (ITT)</population>
        <group_list>
          <group group_id="O1">
            <title>AC-170 0.24%</title>
            <description>1 drop in each eye 3 times daily for up to 6 weeks
AC-170 0.24%</description>
          </group>
          <group group_id="O2">
            <title>AC-170 Vehicle</title>
            <description>1 drop in each eye 3 times daily for up to 6 weeks
AC-170 Vehicle</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Treatment Related Adverse Events</title>
          <description>Adverse events will be measured through study completion</description>
          <population>Intent to Treat (ITT)</population>
          <units>adverse events</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="343"/>
                <count group_id="O2" value="173"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="27"/>
                    <measurement group_id="O2" value="15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Adverse events were collected for the duration of the study. All subjects who received study medication were evaluable for the safety analysis.</time_frame>
      <desc>Throughout the visits, staff collected all Adverse Events reported, elicited or observed.</desc>
      <group_list>
        <group group_id="E1">
          <title>AC-170 0.24%</title>
          <description>1 drop in each eye 3 times daily for up to 6 weeks
AC-170 0.24%</description>
        </group>
        <group group_id="E2">
          <title>AC-170 Vehicle</title>
          <description>1 drop in each eye 3 times daily for up to 6 weeks
AC-170 Vehicle</description>
        </group>
      </group_list>
      <serious_events>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="343"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="173"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Gastroesophageal reflux disease</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="343"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="173"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Substance abuse</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="343"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="173"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>1</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="25" subjects_at_risk="343"/>
                <counts group_id="E2" subjects_affected="15" subjects_at_risk="173"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Visual acuity reduced</sub_title>
                <counts group_id="E1" events="5" subjects_affected="4" subjects_at_risk="343"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="173"/>
              </event>
              <event>
                <sub_title>Conjunctival hyperemia</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="343"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="173"/>
              </event>
              <event>
                <sub_title>Punctate keratitis</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="343"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="173"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Instillation site pain</sub_title>
                <counts group_id="E1" events="7" subjects_affected="6" subjects_at_risk="343"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="173"/>
              </event>
              <event>
                <sub_title>Instillation site erythema</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="343"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="173"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Pharyngitis streptococcal</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="343"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="173"/>
              </event>
              <event>
                <sub_title>Sinusitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="343"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="173"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="343"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="173"/>
              </event>
              <event>
                <sub_title>Migraine</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="343"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="173"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Oropharyngeal pain</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="343"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="173"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There IS an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Michael V.W. Bergamini, PhD - Chief Scientific Officer/Executive Vice President</name_or_title>
      <organization>Nicox Ophthalmics Inc.</organization>
      <phone>817-529-9315</phone>
      <email>bergamini@nicox.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

